1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier
Material Name: Testosterone Cypionate Injection, USP
Trade Name: Depo-Testosterone
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used for hormone replacement therapy

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Reproductive Toxicity: Category 1A
Carcinogenicity: Category 1B

Label Elements
Signal Word: Danger
Hazard Statements: H360FD - May damage fertility. May damage the unborn child.
H350 - May cause cancer

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
SAFETY DATA SHEET

Material Name: Testosterone Cypionate Injection, USP
Revision date: 29-Jun-2016

Page 2 of 8
Version: 4.3

Other Hazards
Note: No data available

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENZYL BENZOATE</td>
<td>120-51-4</td>
<td>204-402-9</td>
<td>Acute Tox. 4 (H302)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Aquatic Chronic 2 (H411)</td>
<td></td>
</tr>
<tr>
<td>Benzyl Alcohol</td>
<td>100-51-6</td>
<td>202-859-9</td>
<td>Acute Tox.4 (H302)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Tox.4 (H332)</td>
<td></td>
</tr>
<tr>
<td>Testosterone Cypionate</td>
<td>58-20-8</td>
<td>200-368-4</td>
<td>Repr. 1A (H360FD) Carc. 1B (H350)</td>
<td>10-20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cottonseed Oil</td>
<td>8001-29-4</td>
<td>232-280-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:** None
5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion Products: Carbon dioxide, carbon monoxide

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Benzyl Alcohol

- Bulgaria OEL - TWA: 5.0 mg/m³
- Czech Republic OEL - TWA: 40 mg/m³
- Finland OEL - TWA: 10 ppm
- Latvia OEL - TWA: 45 mg/m³
- Lithuania OEL - TWA: 5 mg/m³
- Poland OEL - TWA: 5 mg/m³

Testosterone Cypionate
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Clear

Odor: No data available.
Odor Threshold: No data available.

Molecular Formula: Mixture
Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: No data available

pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Testosterone propionate

No data available
Benzy alcohol
No data available

BENZYL BENZOATE
No data available
Cottonseed oil
No data available

Testosterone Cypionate
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
   Oxidizing Properties: No data available
   Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
   Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
   Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information in this section describes the hazards of various forms of the active ingredient. Adverse reproductive effects seen in repeat-dose animal studies are consistent with the pharmacologic action of this drug and are expected to be relevant to humans.
Known Clinical Effects: Clinical use has caused effects on reproductive system, including prolonged erection (priapism), breast development in males (gynecomastia), loss of libido, decreased sperm count, impairment of male fertility, development of male characteristics (masculinization), development of male characteristics in the female fetus, impairment of female fertility. Clinical use of this drug has caused prostate cancer, liver cancer.

Acute Toxicity: (Species, Route, End Point, Dose)

Testosterone propionate
- Rat Oral LD50 1000 mg/kg
- Mouse Oral LD 50 1350 mg/kg

Benzyl Alcohol
- Rat Oral LD50 1230 mg/kg
- Rat Para-periosteal LD50 53 mg/kg
- Rat Inhalation LC50 >4.178 mg/L

BENZYL BENZOATE
- Rat Oral LD50 1680 mg/kg

Cottonseed Oil
- Rat Oral LD50 > 90 ml/kg

Testosterone Cypionate
- Mouse Para-periosteal LD 50 > 1000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.
11. TOXICOLOGICAL INFORMATION

Irritation / Sensitization: (Study Type, Species, Severity)

Benzyl Alcohol
- Eye Irritation: Rabbit, Severe
- Skin Irritation: Rabbit, Minimal
- Skin Irritation: Guinea Pig, Moderate

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Testosterone propionate
- 5 Day(s) Mouse Oral 1000 mg/kg/day NOAEL None identified
- 28 Day(s) Monkey Subcutaneous 2.7 mg/kg/day LOAEL Endocrine system

Testosterone Cypionate
- 5 Day(s) Mouse Oral 200 mg/kg LOAEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Testosterone propionate
- Embryo / Fetal Development: Monkey Subcutaneous 1.25 mg/kg/day LOEL Teratogenic
- Embryo / Fetal Development: Rat Subcutaneous 0.4 mg/kg NOEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Testosterone Cypionate
- Bacterial Mutagenicity (Ames)

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Testosterone propionate
- Not specified Rat Subcutaneous 80-100 mg LOEL Tumors, Male reproductive system

Carcinogen Status: See below

Testosterone propionate
- IARC: Group 2A (Probably Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Benzyl Alcohol
- *Pimephales promelas* (Fathead Minnow) EPA LC50 96 Hours 460 mg/L
- *Daphnia magna* (Water Flea) OECD EC50 48 Hours 230 mg/L
- *Pseudokirchneriella subcapitata* (Green Alga) OECD EC50 72 Hours 500 mg/L
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:
Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

BENZYL BENZOATE

<table>
<thead>
<tr>
<th>Regulation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>204-402-9</td>
</tr>
</tbody>
</table>
15. REGULATORY INFORMATION

Benzyl Alcohol

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS):                  | Present   |
| EU EINECS/ELINCS List              | 202-859-9 |

Cottonseed Oil

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS):                  | Present   |
| EU EINECS/ELINCS List              | 232-280-7 |

Testosterone Cypionate

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65           | Developmental toxicity initial date 10/1/91 Carcinogen (Testosterone and its Esters) 4/1/88 Male Reproductive Toxicity (Anabolic Steroids) 4/1/90 Female Reproductive Toxicity (Anabolic Steroids) 4/1/90 |
| U.S. Drug Enforcement Administration: | Schedule III N Controlled Substance |
| Australia (AICS):                  | Present |
| EU EINECS/ELINCS List              | 200-368-4 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.
Carcinogenicity-Cat.1B; H350 - May cause cancer
Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled
Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

Data Sources:
Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision:
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 29-Jun-2016
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet